News
BMEA
1.750
+1.16%
0.020
Weekly Report: what happened at BMEA last week (0331-0404)?
Weekly Report · 6d ago
IVEY PMI Reading Due Next Week in Canada
Barchart · 04/04 14:22
Biomea Fusion Price Target Cut to $3.00/Share From $11.00 by Barclays
Dow Jones · 04/02 14:26
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Dow Jones · 04/02 14:26
Barclays Maintains Equal-Weight on Biomea Fusion, Lowers Price Target to $3
Benzinga · 04/02 14:15
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
NASDAQ · 04/02 13:35
BIOMEA FUSION INC. <BMEA.O>: BARCLAYS CUTS TARGET PRICE TO $3 FROM $11
Reuters · 04/02 10:56
Biomea Fusion price target lowered to $3 from $11 at Barclays
TipRanks · 04/02 09:35
Barclays Sticks to Their Hold Rating for Biomea Fusion (BMEA)
TipRanks · 04/02 08:58
U.S. RESEARCH ROUNDUP- Beacon Roofing Supply, Carvana, Reinsurance Group of America
Reuters · 04/02 07:13
Biomea Fusion’s Strategic Shift: A Year of Transformation
TipRanks · 04/02 03:56
BIOMEA FUSION, INC. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/01 20:01
Biomea Fusion Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 04/01 13:31
Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
TipRanks · 04/01 12:55
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 04/01 11:31
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
TipRanks · 04/01 10:55
Biomea Fusion GAAP EPS of -$0.81 beats by $0.12
Seeking Alpha · 03/31 21:07
Biomea Fusion reports Q4 EPS (81c), consensus (93c)
TipRanks · 03/31 20:30
*Biomea Fusion: COVALENT-112 (T1D) Open Label Data Anticipated in 2H >BMEA
Dow Jones · 03/31 20:12
*Biomea Fusion: COVALENT-111 (T2D) 52-Week Data Anticipated in 2H >BMEA
Dow Jones · 03/31 20:12
More
Webull provides a variety of real-time BMEA stock news. You can receive the latest news about Biomea Fusion, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BMEA
More
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).